SPOTLIGHT -
Treatment Comparison: Somnolence/Sedation With Dopamine Partial Agonists vs D2 Receptor Antagonists
Recent research reveals dopamine partial agonists significantly reduce somnolence in major depressive disorder and schizophrenia compared with D2 receptor antagonists.
New Data: Cariprazine Adjunctive to Antidepressant Therapy for Anhedonia Symptoms
Cariprazine shows promise as a long-term adjunctive treatment for anhedonia in major depressive disorder, according to new poster data presented at the ASCP Annual Meeting.
Positive Phase 2 Results on NBI-1117568 for Schizophrenia Presented at 2025 ASCP Annual Meeting
Neurocrine Biosciences reveals promising phase 2 results for NBI-1117568, a novel treatment for schizophrenia, showing significant symptom improvement over placebo.
Looking Ahead to the ASCP Annual Meeting With Joseph F. Goldberg, MD, and Anita H. Clayton, MD
Dr Goldberg and Dr Anita share previews of the upcoming ASCP Annual Meeting in Scottsdale, Arizona.
Phase 2b Study Explores Efficacy of MM-120 for the Treatment of GAD
Experts shared the study results in a poster presentation at the 2024 ASCP Annual Meeting.
Phase 1 Study Findings Support Efficacy of ALTO-101 for the Treatment of Cognitive Impairment in Schizophrenia
Seltorexant, Major Depressive Disorder, and Insomnia: Thoughts on the New Data
Andrew Krystal, MD, and Wayne Drevets, MD, share their thoughts on the recent seltorexant data presented at the 2024 ASCP Annual Meeting.
An Update on GLP-1 Receptor Agonists as Pharmacotherapies for AUD
How effective are these agents for AUD treatment? An expert shares highlights from his 2024 ASCP Annual Meeting Pharmaceutical Pipeline Update presentation.
Poster Explores Safety, Efficacy of Seltorexant for MDD, Insomnia
A poster presented at the 2024 ASCP Annual Meeting discussed the results of a study on the treatment for depressive symptoms in this patient population.
Post Hoc Analysis Explores Risk-Benefit Profile of KarXT
A poster presented at the 2024 ASCP Annual Meeting discussed the results of a study on the efficacy and tolerability of the investigational schizophrenia treatment.
Efficacy of Esketamine Nasal Spray for TRD in Real-World Clinical Settings
How effective is this treatment in real-world clinical settings? Experts explore this in a poster presented at the 2024 ASCP Annual Meeting.
Evaluating the Efficacy of Lumateperone for MDD and Bipolar Depression With Mixed Features
A poster presented at the 2024 ASCP Annual Meeting discussed the results of a study analyzing the treatment’s safety and efficacy in this patient population.
Nonpharmacological Interventions for MDD and Their Effects on Neuroplasticity
A poster presented at the 2024 ASCP Annual Meeting discusses the results of a systematic literature review.
Research and Opportunities at the 2024 ASCP Annual Meeting
Erin Crown, MHS, PA-C, shares her thoughts on ASCP, the annual meeting, and more.
Early Improvement of Symptoms in Bipolar 1 Depression
Anita H. Clayton, MD, gives a preview of her upcoming poster presentation at the 2024 ASCP Annual Meeting.
Pseudospecific and Transdiagnostic Symptom Targeting in Clinical Trials
Joseph F. Goldberg, MD, gives a preview of his upcoming panel presentation at the 2024 ASCP Annual Meeting.
Exciting Possibilities at ASCP 2024
Anita H. Clayton, MD, welcomes us all to the 2024 ASCP Annual Meeting!
Efficacy of Semaglutide for the Treatment of Substance Use Disorders
An analysis presented at the ASCP Annual Meeting explored the safety and tolerability of the treatment for alcohol and tobacco use disorders.
Efficacy of Brexpiprazole and Sertraline for the Treatment of PTSD
A poster at the 2024 ASCP Annual Meeting shared data from 3 randomized clinical trials on the safety and tolerability of this treatment combination.
Understanding the Effects of Pharmacotherapy Through Passive Data Collection
An expert discusses the potential of smartphones as treatment measurement tools at the 2024 ASCP Annual Meeting.
Efficacy of Modafinil for Treatment of Neurocognitive Impairment in Bipolar Disorder
An expert discusses the role of cognition in bipolar disorder and the potential of modafinil as a treatment for it at the 2024 ASCP Annual Meeting.
Revisiting Modafinil/Armodafinil for the Treatment of Bipolar Disorder
An expert shares some lessons learned from prior research on the treatment and suggestions for a way forward at the 2024 ASCP Annual Meeting.
Navigating New Treatments for PTSD
An expert shares highlights from her panel presentation at the 2024 ASCP Annual Meeting.
Poster Preview: ASCP 2024
Attending the 2024 ASCP Annual Meeting? Be sure to catch these upcoming poster presentations.
